Merck KGaA to Buy Bio-Techne for $11.3B at $73/Share Premium
MRK•Germany's Merck KGaA agreed to acquire Bio-Techne for $11.3 billion, paying $73 per share—a 24% premium. The deal, funded with cash reserves and new debt and expected to close by early 2027, aims to deliver roughly €140 million in annual cost synergies for its life sciences unit.
1. Acquisition Details
Germany's Merck KGaA has agreed to acquire Bio-Techne Corp in a transaction valued at $11.3 billion, offering $73 per share, representing a 24% premium over recent trading averages. This marks one of the largest deals in the life-sciences sector this year and Merck's biggest purchase since the 2015 Sigma-Aldrich acquisition.
2. Strategic Rationale
The acquisition bolsters Merck's life sciences division by adding Bio-Techne's drug discovery tools, diagnostic technologies, biopharmaceutical manufacturing support and research reagents. Bio-Techne's portfolio of proteins, antibodies and analytical instruments complements Merck's existing research infrastructure and expands its global laboratory tools footprint.
3. Financing and Timeline
Merck plans to fund the deal through a mix of existing cash reserves and newly issued debt. The transaction is subject to regulatory approvals and Bio-Techne shareholder consent, with completion anticipated in late 2026 or early 2027.
4. Expected Synergies and Risks
Merck projects approximately €140 million in annual cost synergies post-integration, driven by consolidated operations and cross-selling opportunities. Key risks include regulatory approval delays and the challenges of integrating two large research-focused organizations.
